Trial Profile
A real-world study evaluating the sequencing patterns of ramucirumab and immune checkpoint inhibitors in platinum-treated patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2018
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology